These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 10795085)

  • 1. Lamivudine (3TC)-induced contact dermatitis.
    Smith KJ; Buckley R; Skelton H
    Cutis; 2000 Apr; 65(4):227-9. PubMed ID: 10795085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe skin rash with lamivudine in HIV infected patients: some unusual case reports.
    Modak D; Guha SK
    Indian J Pharmacol; 2013; 45(3):298-300. PubMed ID: 23833379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
    Brogly SB; Ylitalo N; Mofenson LM; Oleske J; Van Dyke R; Crain MJ; Abzug MJ; Brady M; Jean-Philippe P; Hughes MD; Seage GR
    AIDS; 2007 May; 21(8):929-38. PubMed ID: 17457086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy.
    Khouri S; Cushing H
    AIDS Read; 2000 Oct; 10(10):602-6. PubMed ID: 11068807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prenatal exposure to Zidovudine and Lamivudine on brainstem auditory evoked potentials in infants from HIV-infected women.
    Poblano A; Figueroa L; Figueroa-Damián R; Schnaas L
    Proc West Pharmacol Soc; 2004; 47():46-9. PubMed ID: 15633610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
    Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
    J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
    Sankatsing RR; Wit FW; Pakker N; Vyankandondera J; Mmiro F; Okong P; Kastelein JJ; Lange JM; Stroes ES; Reiss P
    J Infect Dis; 2007 Jul; 196(1):15-22. PubMed ID: 17538878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
    Nelson M; Azwa A; Sokwala A; Harania RS; Stebbing J
    AIDS; 2008 Jul; 22(11):1374-6. PubMed ID: 18580619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
    Launay O; Gérard L; Morand-Joubert L; Flandre P; Guiramand-Hugon S; Joly V; Peytavin G; Certain A; Lévy C; Rivet S; Jacomet C; Aboulker JP; Yéni P;
    Clin Infect Dis; 2002 Nov; 35(9):1096-105. PubMed ID: 12384844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions between apricitabine and other deoxycytidine analogues.
    Bethell R; De Muys J; Lippens J; Richard A; Hamelin B; Ren C; Collins P
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2948-53. PubMed ID: 17517847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.